Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity

• Main Authors: Katharina Schütz (Author), Sophia Theres Pallenberg (Author), Julia Kontsendorn (Author), David DeLuca (Author), Cinja Sukdolak (Author), Rebecca Minso (Author), Tina Büttner (Author), Martin Wetzke (Author), Christian Dopfer (Author), Annette Sauer-Heilborn (Author), Felix C. Ringshausen (Author), Sibylle Junge (Author), Burkhard Tümmler (Author), Gesine Hansen (Author), Anna-Maria Dittrich (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and in June 2021 for pwCF ≥6 yrs of age. In this single...